Unknown

Dataset Information

0

Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease: room-temperature X-ray and neutron crystallography, binding thermodynamics, and antiviral activity.


ABSTRACT: The COVID-19 pandemic continues to disrupt everyday life, with constantly emerging SARS-CoV-2 variants threatening to render current vaccines ineffective. Small-molecule antivirals can provide an important therapeutic treatment option that is subject to challenges caused by the virus variants. The viral main protease (M pro ) is critical for the virus replication and thus is considered an attractive drug target for specific protease inhibitors. We performed the design and characterization of three reversible covalent hybrid inhibitors BBH-1, BBH-2 and NBH-2, whose structures were derived from those of hepatitis C protease inhibitors boceprevir and narlaprevir. A joint X-ray/neutron structure of the M pro /BBH-1 complex demonstrated that a Cys145 thiolate reaction with the inhibitor’s keto-warhead creates a negatively charged oxyanion, similar to that proposed for the M pro -catalyzed peptide bond hydrolysis. Protonation states of the ionizable residues in the M pro active site adapt to the inhibitor, which appears to be an intrinsic property of M pro . Structural comparisons of the hybrid inhibitors with PF-07321332 revealed unconventional interactions of PF-07321332 with M pro which may explain its more favorable enthalpy of binding and consequently higher potency. BBH-1, BBH-2 and NBH-2 demonstrated comparable antiviral properties in vitro relative to PF-07321332, making them good candidates for further design of improved antivirals.

SUBMITTER: Kneller D 

PROVIDER: S-EPMC8845512 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease: room-temperature X-ray and neutron crystallography, binding thermodynamics, and antiviral activity.

Kneller Daniel D   Li Hui H   Phillips Gwyndalyn G   Weiss Kevin K   Zhang Qiu Q   Arnould Mark M   Jonsson Colleen C   Surendranathan Surekha S   Parvathareddy Jyothi J   Blakeley Matthew M   Coates Leighton L   Louis John J   Bonnesen Peter P   Kovalevsky Andrey A  

Research square 20220211


The COVID-19 pandemic continues to disrupt everyday life, with constantly emerging SARS-CoV-2 variants threatening to render current vaccines ineffective. Small-molecule antivirals can provide an important therapeutic treatment option that is subject to challenges caused by the virus variants. The viral main protease (M <sup>pro</sup> ) is critical for the virus replication and thus is considered an attractive drug target for specific protease inhibitors. We performed the design and characteriza  ...[more]

Similar Datasets

| S-EPMC9046211 | biostudies-literature
| S-EPMC10397204 | biostudies-literature
| S-EPMC5297917 | biostudies-literature
| S-EPMC8562657 | biostudies-literature
| S-EPMC4491318 | biostudies-literature
| S-EPMC5644340 | biostudies-literature
| S-EPMC9067118 | biostudies-literature
| S-EPMC10922772 | biostudies-literature
| S-EPMC6608623 | biostudies-literature
| S-EPMC3182744 | biostudies-literature